Fluor Corp. (Irving, Tex.; www.fluor.com) has been awarded an engineering, procurement, construction and construction management contract by Novo Nordisk (www.novonordisk.com) for its new $2-billion diabetes active pharmaceutical ingredient (API) manufacturing facility in Clayton, N.C. Fluor has been providing basic design services since Novo Nordisk announced plans for the new facility in August 2015 and now will be executing the full scope of work. Fluor booked its $1.2 billion value of the investment in the fourth quarter of 2016.
“Fluor is honored to have the opportunity to assist Novo Nordisk in building this world-class facility in North Carolina to provide modern treatments to diabetes patients,” says Juan G. Hernández, president of Fluor’s Life Sciences and Advanced Manufacturing business. “This project is the single largest life sciences facility investment in North Carolina’s history, which fits well with Fluor’s legacy of building numerous significant life sciences and manufacturing projects in the southeast United States.”
The new facility will measure more than 830,000 square feet, the equivalent of nearly seven football fields, and will produce life-saving medicines for use by patients around the world.
Nearly 2,500 craft employees and subcontractor jobs are expected at peak construction with about 700 new jobs at the facility when it is completed. Fluor participated in a groundbreaking event this past spring, and its Greenville, South Carolina office is leading the project, leveraging Fluor’s global resources as needed. Construction is expected to be completed in mid-2019.